Physician profile
Deepak Patel
NPI 1114989910
$758.50
in general payments reported to CMS, 2019-2025
20 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.25 · 2020: $80.66 · 2021: $29.11 · 2022: $49.01 · 2023: $73.17 · 2024: $175 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $139.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $59.14 | 2020 | |
| Inspire Medical Systems, INC. | $57.46 | 2023-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $51.47 | 2019 | |
| Glaxosmithkline, LLC. | $51.08 | 2021-2025 | Trelegy Ellipta |
| Cook Medical LLC | $39.51 | 2022-2023 | Zilver Vena |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.11 | 2024-2025 | Lifevest |
| Abbvie INC. | $32.59 | 2021-2024 | |
| Exact Sciences Corporation | $31.26 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $30.57 | 2025 | Otezla, Repatha |
| Lilly USA, LLC | $29.52 | 2023-2024 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $29.47 | 2025 | Watchman Flx |
| Amarin Pharma, INC. | $26.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.29 | 2024 | |
| Pfizer INC. | $22.91 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.52 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $20.83 | 2024 | Opsumit |
| Edwards Lifesciences Corporation | $17.10 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.99 | 2023 | Xarelto |
| Dexcom, INC. | $16.31 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.